Is there U-turn from insulin back to pills in diabetes?

Current Vascular Pharmacology

Volumn 12, Issue 4, 2014, Pages 617-626

  Ertek, Sibel ^a   Cetinkalp, Sevki ^b  

^a Sanliurfa Education and Research Hospital   (Turkey)

^b Department of Endocrinology and Metabolic Diseases ^*  (Turkey)

Author keywords

Amylin; Beta cell; Glucotoxicity; Insulin; Oral antidiabetics; Type 2 diabetes

Indexed keywords

INSULIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; ROSIGLITAZONE;

APPETITE; ARTICLE; DIABETES MELLITUS; GLUCOTOXICITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; NONHUMAN; WEIGHT GAIN; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRACTICE GUIDELINE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; PRACTICE GUIDELINES AS TOPIC; THIAZOLIDINEDIONES;

EID: 84904734049     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990122     Document Type: Article

References (96)

1. Garber AJ. Incretin effects on beta cell function, replication and mass. Diabetes Care 2011; 34(Suppl2): S258-S263.
2. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diab Res Clin Pract 1998; 40 Suppl: S21-S25.
3. Riddle MC. Managing type 2 diabetes: lessons from the UKPDS. Diabetes Spectrum 2000; 13: 194.
4. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya Y. Beta cell death and mass in syngenetically transplanted islets exposed to short and long-term hyperglycemia. Diabetes 2002; 51: 66-72.
5. Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes, free fatty acids and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-78.
6. Weir GC, Bonner-Weir S. Five stages of evolving α-cell dysfunction during progression to diabetes. Diabetes 2004; 53(Suppl. 3): S16-S21.
7. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus J Am Med Assoc 2002; 287: 2563-69.
8. Nathan DM, Cleary PA, Backlund JY, et al. Writing team fort he Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005; 353: 2643-53.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008; 359: 1577-89.
10. Origin Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 2012; 367: 319-28.
11. Chen A, Huang Z, Wan X, et al. Attitudes towards diabetes affect maintainance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continouous subcutaneous insulin infusion treatment. Diabetes Care 2012; 35: 474-81.
12. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
13. UK Prospective Diabetes Study Group: UK Prospective Diabetes 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
14. Riddle MC. Managing type 2 diabetes over time: Lessons from the UKPDS. Diabetes Spectrum 2000; 13: 194.
15. Ceriello A, Esposito K, Inhat M, Thorpe J, Giuliano D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin End Metab 2009; 94: 2751-6.
16. Brownlee M. The pathobiology of diabetic complications. Diabetes 2005; 54: 1615-25.
17. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993; 42: 80-9.
18. Heiling CW, Concepcion LA, Riser BL, et al. Overexpression of glucose transporters in rat mesengial cells cultured in normal glucose milieu mimics the diabetic phenotype. J Cin Invest 1995; 96: 1802-14.
19. Leahy JL. Cell dysfunction in Type 2 Diabetes Mellitus. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, Eds., Joslin's Diabetes Mellitus, 14th edition, Lippincott Williams&Wilkins; Boston 2005; pp 449-61.
20. Kilpatrick D, Robertson RP. Differentiation between glucoseinduced desensitization of insulin secretion and beta cell exhaustion in the HIT-T15 cell line. Diabetes 1998; 47: 606-11.
21. Grodsky GM, Bolaffi JL. Desensitization of the insulin-secreting beta cell. J Cell Biochem 1992; 48: 3-11.
22. Ling Z, Pipeleers DG. Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest 1996; 98: 2805-12.
23. Leahy JL, Weir GC. Beta cell dysfunction in hyperglycemic rat models: recovery of glucose-induced insulin secretion with lowering of the ambient glucose level. Diabetologia 1991; 34: 640-7.
24. Jörns A, Klempnauer J, Tiedge M, Lenzen S. Recovery of pancreatic beta cells in response to long-term normoglycemia after pancreas or islet transplantation in severely streptozotocin diabetic adult rats. Pancreas 2001; 23: 186-96.
25. Kaneto H, Kawamori D, Matsuoka TA, Kajimoto Y, Yamasaki Y. Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 2005; 12: 529-33.
26. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391-406.
27. Cnop M, Igoillo-Esteve M, Cunha DA, Ladrière L, Eizirik DL. An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. Biochem Soc Trans 2008; 36: 909-15.
28. Jürgen M, Sturis J, Katschinsky M, et al. Acute hyperglycemia alters the ability of the normal α-cell to sense and respond to glucose. Am J Physiol Endocrinol Metab 2002; 282: E917-E922.
29. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 2003; 26 (Suppl. 1): S33-S50.
30. Del Prato S, Felton AM, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005; 59: 1345-55.
31. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007; 22(4): 453-8.
32. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27(7): 1535-40.
33. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003; 9(3): 213-7.
34. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 2008; 34(3): 511-7.
35. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997; 278: 1663-9.
36. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46(3): 239-46.
37. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 (Suppl 3): S18-24.
38. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28(11): 2673-9.
39. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med 1997; 14 (Suppl 2): S9-13.
40. Zraika S, Hull RL, Verchere CB, et al. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 2010; 53(6): 1046-56.
41. Figueroa H, Peddi D, Osborne JM, et al. Modeling the Interface between Islet Amyloid Polypeptide and Insulin-Based Aggregation Inhibitors: Correlation to Aggregation Kinetics and Membrane Damage. J Chem Inf Model 2012; 52(5): 1298-307.
42. Knight JD, Williamson JA, Miranker AD. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Science 2008; 17: 1-7.
43. Larson JL, Miranker AD. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J Mol Biol 2004; 335: 221-31.
44. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates α-cell expression of IL-1 receptor antagonist and release of IL-1 αin human islets. Proc Natl Acad Sci USA 2004; 101: 8138-43.
45. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-65.
46. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of α-cell function. Diabetes Care 2004; 27: 2597-602.
47. Tseng YH, Ueki K, Kriauciunas KM, Kahn CR. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J Biol Chem 2002; 277: 31601-611.
48. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007; 99: 15B-26B.
49. Hennige AM, Ozcan U, Okada T, et al. Alterations in growth and apoptosis of insulin receptor substrate-1-deficient α-cells. Am J Physiol Endocrinol Metab 2005; 289: E337-E346.
50. Wajchenberg BL. α-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
51. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
52. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic α-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
53. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic α-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-22.
54. Gerstein HC, Yusuf S, Bosch J, et al. on behalf of the DREAM trial investigators 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368: 1096-1105.
55. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserved residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996; 45: 1427-30.
56. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic α-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-7.
57. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced α-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-6.
58. Iwakura T, Fujimoto S, Kagimoto S, et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Res Commun 2000; 27: 422-8.
59. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-7.
60. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both α-cell replication and neogenesis, resulting in increased α-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
61. Li Y, Hansotia Y, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates α-cell apoptosis. J Biol Chem 2003; 278: 471-8.
62. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents α-cell glucolipotoxicity. Diabetologia 2004; 47: 806-15.
63. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with Type 2 diabetes. J Clin Endocrinol Metab 2005; 90, 5991-7.
64. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Characterization of α-cell function improvement by liraglutide: modeling analysis of 24-h tests. Diabetes 2006; 55: A124.
65. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases α-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
66. Mu J, Woods J, Zhou Y-P, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic α-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
67. Duttaroy A, Voelker F, Merriam LQ, Zhang X, Ren X, Burkey B. The DPP-4 inhibitor Vildagliptin increases pancreatic α-cell neogenesis and decreases apoptosis. Diabetes 2005; 54(Suppl 1): A141 [Abstract 572-P].
68. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed α-cell function in patients with Type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-94.
69. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 2632-7.
70. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet α-cells. Diabetes Metab Res Rev 2003; 19: 115-23.
71. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse diabetes. Diabetes 2000; 49: 741-8.
72. Zhou J, Wang S, Pineyro MA, Egan JM 1999 Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon-and insulin-producing cells. Diabetes 1999; 48: 2358-66.
73. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-58.
74. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin Investig Drugs 2009; 18: 1495-1503.
75. Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
76. Andraws R, Brown DL. Effect of inhibition of the reninangiotensin system on development of Type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-1012.
77. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73.
78. Scheen AJ. Prevention of Type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64: 2537-65.
79. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in Type 2 diabetes mellitus. N Engl J Med 2007; 356, 1517-26.
80. Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011; 187(5): 2755-65.
81. Khalaileh A, Gonen-Gross T, Magenheim J, et al. Determinants of pancreatic beta-cell regeneration. Diabetes Obes Metab 2008; 10 Suppl 4: 128-35.
82. McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am 2012; 41(1): 57-87.
83. Donner T, Munoz M. Update on Insulin Therapy for Type 2 Diabetes. J Clin Endocrinol Metab 2012; 97: 1405-13.
84. Cesur M, Cesur A. Double diabetes: possible but unpublished complication of insulin pump therapy. J Diabetes Complicat 2008; 22(2): 147-9.
85. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006; 8(suppl 2): S19-26.
86. Cohen DH, Leroith D. Obesity, type 2 diabetes and cancer: the insulin and insulin-like growth factor connection. Endocr Relat Cancer 2012 May 16. [Epub ahead of print].
87. Bertacca A, Ciccarone A, Cecchetti P, et al. Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. Metabolism 2005; 54(12): 1687-93.
88. Brüning JC, Gautam D, Burks DJ, et al. Role of Brain Insulin Receptor in Control of Body Weight and Reproduction. Science 2000; 289: 2122-5.
89. Ampudia-Blasco FJ, Rossetti P, Ascaso JF. Basal plus basal-bolus approach in type 2 diabetes. Diabetes Technol Ther 2011; 13 (Suppl 1): S75-83.
90. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13(9): 814-22.
91. Herman WH, Buse JB, Arakaki RF, et al. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. Endocr Pract 2011; 17(4): 563-7.
92. Liao L, Yang M, Qiu LL, Mou YR, Zhao JJ, Dong JJ. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone. Chin Med J (Engl) 2010; 123(24): 3684-8.
93. Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 2011; 10: 65.
94. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and metaanalysis. PLoS One 2009; 4(7): e6112.
95. Odawara M, Ohtani T, Kadowaki T. Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study Subanalysis. Diabetes Technol Ther 2012 Apr 23. [Epub ahead of print].
96. Li YB, Zhu HL, Yao B, et al. [Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes]. Zhonghua Yi Xue Za Zhi 2005; 85(9): 602-5.